LewisJTOliveiraAMNascimentoAG, et al.Low-grade sinonasal sarcoma with neural and myogenic features: a clinicopathologic analysis of 28 cases. Am J Surg Pathol. 2012 Apr;36(4):517-525. doi: 10.1097/PAS.0b013e3182426886. PMID: 22301502.
2.
GrossJFritchieK. Soft tissue special issue: biphenotypic sinonasal sarcoma: a review with emphasis on differential diagnosis. Head Neck Pathol. 2020 Mar;14(1):33-42. doi: 10.1007/s12105-019-01092-4. Epub 2020 Jan 16. PMID: 31950469; PMCID: PMC7021886.
3.
WangXBledsoeKLGrahamRP, et al.Recurrent PAX3-MAML3 fusion in biphenotypic sinonasal sarcoma. Nat Genet. 2014 Jul;46(7):666-668. doi: 10.1038/ng.2989. Epub 2014 May 25. PMID: 24859338; PMCID: PMC4236026.
4.
JoVYMariño-EnríquezAFletcherCDMHornickJL. Expression of PAX3 distinguishes biphenotypic sinonasal sarcoma from histologic mimics. Am J Surg Pathol. 2018 Oct;42(10):1275-1285. doi: 10.1097/PAS.0000000000001092. PMID: 29863547.
5.
BuckinghamMRelaixF. PAX3 and PAX7 as upstream regulators of myogenesis. Semin Cell Dev Biol. 2015 Aug;44:115-125. doi: 10.1016/j.semcdb.2015.09.017. Epub 2015 Sep 28. PMID: 26424495.
HuangSCGhosseinRABishopJA,et al.Novel PAX3-NCOA1 fusions in biphenotypic sinonasal sarcoma with focal rhabdomyoblastic differentiation. Am J Surg Pathol. 2016 Jan;40(1):51-59. doi: 10.1097/PAS.0000000000000492. PMID: 26371783; PMCID: PMC4679641.
8.
FritchieKJJinLWangX, et al.Fusion gene profile of biphenotypic sinonasal sarcoma: an analysis of 44 cases. Histopathology. 2016 Dec;69(6):930-936. doi: 10.1111/his.13045. Epub 2016 Sep 23. PMID: 27454570.
9.
CoppockJDStelowEB. Low-grade biphenotypic sinonasal sarcoma: case report, current understanding, and differential diagnosis. AJSP Rev Rep. 2021;26(4):220-225. doi: 10.1097/PCR.0000000000000453
10.
SchäferBWCzernyTBernasconiMGeniniMBusslingerM. Molecular cloning and characterization of a human PAX-7 cDNA expressed in normal and neoplastic myocytes. Nucleic Acids Res. 1994 Nov 11;22(22):4574-4582. doi: 10.1093/nar/22.22.4574. PMID: 7527137; PMCID: PMC308503.
11.
SealePSabourinLAGirgis-GabardoAMansouriAGrussPRudnickiMA. Pax7 is required for the specification of myogenic satellite cells. Cell. 2000 Sep 15;102(6):777-786. doi: 10.1016/s0092-8674(00)00066-0. PMID: 11030621.
12.
BennicelliJLAdvaniSSchäferBWBarrFG. PAX3 And PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. Oncogene. 1999 Jul 29;18(30):4348-4356. doi: 10.1038/sj.onc.1202812. PMID: 10439042.
13.
CharvilleGWWangWLIngramDR, et al.EWSR1 Fusion proteins mediate PAX7 expression in Ewing sarcoma. Mod Pathol. 2017 Sep;30(9):1312-1320. doi: 10.1038/modpathol.2017.49. Epub 2017 Jun 23. PMID: 28643791.
14.
TokiSWakaiSSekimizuM,et al.PAX7 Immunohistochemical evaluation of Ewing sarcoma and other small round cell tumours. Histopathology. 2018 Oct;73(4):645-652. doi: 10.1111/his.13689. Epub 2018 Aug 2. PMID: 29920735.
15.
MartinERadomskiSHarleyE. Sarcomas of the paranasal sinuses: an analysis of the SEER database. Laryngoscope Investig Otolaryngol. 2019 Jan 15;4(1):70-75. doi: 10.1002/lio2.245. PMID: 30828621; PMCID: PMC6383302.
